Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Empty street due to coronavirus lockdown

Once a safe and effective COVID-19 vaccine is approved for use by regulators, most countries will not have enough doses to vaccinate everyone. University of Oxford researchers have developed a comprehensive framework to help governments distribute a vaccine effectively and fairly.

The study, made possible with NIHR funding, and published today in the international journal Pharmacoeconomics Open outlines the necessary decisions governments must make regarding allocation of a vaccine. Key considerations must include:

  • the health impacts of COVID-19;
  • reducing the rate of transmission;
  • allowing the economy to return to normal;
  • equity (particularly as COVID-19 has been shown to have disproportionate impacts on socially disadvantaged groups).

While there is a lot of emerging evidence about the impact COVID-19 is having on people’s health and the economy, there is a need to bring this together into an evidence-based framework for understanding the potential benefit of adopting different prioritisation strategies. For example, when determining the degree to which those working in the retail and service sector should be prioritised for vaccination there is a need to take into account: (i) individual health benefits to staff; (ii) societal health benefits via lower transmission to shoppers; (iii) benefits to the economy (e.g. from allowing more shops to open).

Study co-author Dr Laurence Roope, of the Health Economics Research Centre (HERC) in the Nuffield Department of Population Health, said ‘Without a clear plan, governments may be forced into quick decisions and may not realise the full potential of a vaccine.

‘Many governments rely on expert bodies involving clinicians, epidemiologists and health economists that use evidence to guide who should receive new medicines. It should be no different when allocating a COVID-19 vaccine.’

The study suggests that beyond synthesising evidence from research to determine the benefits of a vaccine, it is important that researchers and governments seek public opinion regarding several key aspects of the vaccine distribution:

  • whether governments allow their citizens to purchase a vaccine privately, or solely via public channels such as the UK’s National Health Service (NHS). While most medicines can be purchased privately, the COVID pandemic is much more like a war-time situation and in the past vital goods in limited simply have been rationed.
  • the degree to which a vaccination prioritisation strategy should be focused on health versus wider benefits such as facilitating a safe return to education, protecting jobs and the economy.
  • whether governments should randomly allocate the vaccine if there is not enough vaccine available to cover all individuals assigned the same priority.

Professor Philip Clarke, Director of the Health Economics Research Centre in the Nuffield Department of Population Health, said ‘Engaging with the public by conducting nationally representative surveys would enable researchers and governments to better tailor vaccine strategies. 

‘Given the likelihood that vaccine supplies will be limited, there is a need for a transparent evidence-based framework for prioritising who gets preferential access to it.’

In the race for an effective COVID-19 vaccine, there is a need for governments, researchers and the public to think now about what happens after one of the vaccines crosses the finishing line.

This research was made possible by National Institute for Health Research funding and supported by the NIHR Oxford Biomedical Research Centre.